SIGY · Sigyn Therapeutics, Inc. · Analyst Estimates
$0.03
0.00 (-6.27%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$56,188
Shares
1.61M
Volume · Oct 2
27.05K
Avg daily vol (3M)
30.56K
Analyst Estimates
Compare analyst forecasts for Sigyn Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 09:10 UTC · Publication dates shown per estimate · 2 metric / period groups
FY ending 2022-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|